Navigation Links
Scripps Translational Science Institute joins Jackson Laboratory tumor consortium
Date:6/28/2011

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.

In its role as a consortium member, STSI will provide solid human tumor samples to JAX, which will graft them into mouse models for scientific study. STSI scientists will then have access to the models to conduct research on how to better understand and treat cancer, including the potential for tumor-specific therapies.

JAX will perform the initial genomic characterization of the tumors and will share this data with all participating institutions. STSI is a major research collaboration involving the nonprofit Scripps Health system and The Scripps Research Institute, both of San Diego.

JAX launched the Primary Human Tumor Consortium in 2009. Other participating institutions outside San Diego include the University of Florida, the Swedish Neuroscience Institute in Seattle and UC Davis Cancer Center.

Mouse models that can accept newly resected human tumors offer a highly productive way to develop and test cancer treatments. Mouse models of virtually any kind of cancer can be developed, providing a more individualized approach to finding new treatments.

This approach stands in stark contrast to the standard way of discovering new therapies for cancer, which relies on the use of tumor cell lines. The tumor cell-line approach can be problematic, since genetic mutations naturally occur as those cells divide and reproduce. Consequently, the cells may drift into a different genetic profile and any treatments designed to target the original tumor won't work. Also, the cell-line approach provides insights into which therapies are ineffective, but doesn't predictably prove which ones are effective.

"By joining this consortium, Scripps will contribute to and share in a tumor library that will vastly exceed what any institution could build on its own," said Nicholas J. Schork, Ph.D., director of bioinformatics and biostatistics at STSI. "This shared resource ultimately will greatly expand research capacity for all consortium members, with the goal of accelerating drug development for individualized approaches to each type of tumor."

Located at The Jackson Laboratory's JAX--West facility in Sacramento, Calif., the Primary Human Tumor Consortium seeks additional health care and research partners to speed the development of this tumor library resource. To date, the consortium has engrafted 172 tumors, with tumor sites including prostate, pancreas, lung, kidney, colon, breast, brain and bladder.

"The biomedical research community needs a common, readily accessible resource to support this vital effort," said JAX Executive Vice President and Chief Operating Officer Chuck Hewett, Ph.D. "No single cancer center has a sufficiently broad patient population to meet this need, so we must work together."


'/>"/>

Contact: Joyce Peterson
joyce.peterson@jax.org
207-288-6058
Jackson Laboratory
Source:Eurekalert

Related medicine news :

1. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
2. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
3. Scripps Blood & Marrow Transplant Program Celebrates 30th Anniversary of Providing Life-Saving Care
4. Scripps Memorial Hospital La Jolla First in San Diego to Achieve Magnet Nursing Re-designation
5. Scripps Announces Plans for Region's First Proton Therapy Center; $185 Million Facility to Offer Advanced Care to Cancer Patients
6. Scripps Research scientists share $2 million in Florida state research grants
7. Scripps Center for Executive Health Now Offers Genetic Testing
8. Scripps Research scientists uncover previously unknown natural mechanism that controls cocaine use
9. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
10. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
11. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce ... from U.S. universities who will draw from Siemens’ deep knowledge of product ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections Meeting. ... Almost 10,000 physical therapists across the country are expected to attend this annual convention ... field and network with their colleagues. As in years past, HydroWorx is proud ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
(Date:2/12/2016)... ... , ... AssureVest Insurance Group, a locally owned insurance firm with offices serving ... funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and 3rd grade ... a low-income area and has more than 60 2nd and 3rd graders with learning ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... the Pittsburgh metro area, celebrates the beginning of the latest charity campaign in ... social skills through art. Donations to this worthy cause are currently being accepted ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... The primary goal of this research is to analyze ... of liquid biopsy. Key information the survey seeks to ... liquid biopsy adoption amidst future users - Predominantly used ... Sample inflow to conduct liquid biopsy tests - Preference ... on. - Correlation analysis of sample type and biomarker ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its ... also filed its Quarterly Report on Form 10-Q for the ... Exchange Commission today. --> --> ... --> Net sales for the three months ... $5.4 million from $2.8 million for the three months ended ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
Breaking Medicine Technology: